{"slug":"vesugen","seoKey":"vesugen","displayName":"Vesugen","codes":["KED","T-38","AS-2"],"synonyms":["Lys-Glu-Asp","KED peptide","H-Lys-Glu-Asp-OH","L-lysyl-L-glutamyl-L-aspartic acid","lysyl-glutamyl-aspartic acid (the NLM MeSH supplementary concept heading)","T-38 tripeptide","Vezugen / Везуген (Russian trade name, a food supplement)","Vezugen Lingval (the sublingual solution)"],"legalClass":"research_chemical","identifiers":{"cas":"204271-66-9","pubchemCid":87571363,"inchikey":"LLSUNJYOSCOOEB-GUBZILKMSA-N","formula":"C15H26N4O8","molecularWeight":390.39,"sequence":"KED"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and entirely unknown to the federal databases. Four independent queries on 2026-09-17 returned no match, each with a working control query: no drug label, no application record, no adverse-event record and no entry in the labelling database. There is no substance registration either, which is why no UNII exists. The substance has never been nominated for the compounding bulks list, whose full text was checked in 816 lines; the same list carries other grey-market peptides, so this is an absence and not an oversight. No marketing as a dietary supplement was documented. US distribution runs through the research-chemical channel under a research-use-only label, that is, explicitly not for human use.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22vesugen%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report, no withdrawn application and no orphan designation. The register search returned no product hit on 2026-09-17, but it is JavaScript-driven and produced no machine-readable result list, so the finding is supported additionally by the absence of an international non-proprietary name and of a classification code, which together make a central procedure practically impossible.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=vesugen"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so the injectable form traded in the West is an unauthorised medicinal product and may not be placed on the market. The Russian food-supplement status creates no marketability here: a peptide not consumed as a food to a significant degree in the Union before 15 May 1997 is a novel food and would need its own authorisation, and none was found for this tripeptide. The substance is not named in the schedule to the Anti-Doping Act, whose section on peptide hormones, growth factors, related substances and mimetics lists what it covers by name and exhaustively. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the loading message of its search page on 2026-09-17 and is entirely JavaScript-driven, so no control query could be validated either. This negative finding is NOT independently robust: it rests on the plausibility of the Union-wide absence and on the lack of an international non-proprietary name and classification code.","source":"https://products.mhra.gov.uk/search/?search=vesugen"},{"market":"AU","status":"not_approved","note":"Not registered and not named in the poisons standard, as far as could be established. A direct register query was technically impossible on 2026-09-17: the interface dropped the connection and a second attempt timed out after 60 seconds, so the negative finding on the name is weak. The legal consequence is not: peptides without a register entry count as unapproved therapeutic goods, and import and supply are restricted under the therapeutic goods and customs legislation irrespective of any listing by name.","source":"https://www.tga.gov.au/resources/artg"},{"market":"CA","status":"not_approved","note":"No marketing authorisation, no drug identification number and no natural product number. Two queries on 2026-09-17, by brand name and by active ingredient, both returned an empty array, while a control query for an authorised product returned a complete record with its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=vesugen"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. The authority's site was reachable on 2026-09-17 but its product index is available only through a JavaScript interface or as a periodic spreadsheet, and no extract could be produced. Research through the authority's publications produced no indication of an authorised product with this tripeptide. The finding is supported by the absence of an international non-proprietary name and classification code.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/87571363"],"lastVerified":"2026-09-17","version":"1.0","published":true,"locale":"en","title":"Vesugen: what the studies show, status and safety","summary":"Vesugen is a synthetic chain of three amino acids from a St Petersburg institute, sold as a peptide for blood vessels. Unusually for this series, that label rests on papers that really do measure something in vessel cells. The striking vascular figures that circulate with its name, however, were measured on a different preparation made from cattle vessels. No trial in people has ever been registered, and the one human report that measured safety found pro-oxidant activity and fewer blood-forming cells.","updated":"2026-09-17","url":"https://mypep.app/peptides/vesugen"}